Author

Julio Rodrigo Giròn Berrìos

Observed names: J. Giron Berrios, J. R. Giron Berrios, J.R. Giron Berrios, J.R. Giròn Berrìos, JULIO RODRIGO GIRON BERRIOS, Julio Girï¿½n Berrï¿½os, Julio Gir�n Berr�os, Julio R Giron Berrios, Julio R. Giron Berrios, Julio Rodrigo Giron Berrios, Julio Rodrigo Giron Berríos

Institution: Ospedale di Belcolle

Observed institutions: Policlinico Umberto I, Azienda Sanitaria Locale Viterbo, Ospedale di Belcolle, Sapienza University of Rome

ORCID: 0000-0003-2042-4006

Observed ORCID: 0000-0003-2042-4006

OpenAlex ID: A5073273844

Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial

2026 · Serena Porcari, Chiara Ciccarese, et al. · Nature Medicine · 67

Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigens

2020 · Alessio Grimaldi, Ilenia Cammarata, et al. · Communications Biology · 52

LBA77 Fecal microbiota transplantation (FMT) versus placebo in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma: Preliminary results of the randomized phase II TACITO trial

2024 · C. Ciccarese, S. Porcari, et al. · Annals of Oncology · 38

Evaluation of the efficacy of cisplatin–etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNEC

2017 · Arsela Prelaj, Sara Elena Rebuzzi, et al. · ERJ Open Research · 29

Therapeutic approach in glioblastoma multiforme with primitive neuroectodermal tumor components: Case report and review of the literature

2018 · Arsela Prelaj, Sara Rebuzzi, et al. · Oncology Letters · 25

Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study

2021 · F. Nelli, A. Fabbri, et al. · Annals of Oncology · 16

Early Changes in LIPI Score Predict Immune-Related Adverse Events: A Propensity Score Matched Analysis in Advanced Non-Small Cell Lung Cancer Patients on Immune Checkpoint Blockade

2024 · Fabrizio Nelli, Agnese Fabbri, et al. · Cancers · 10

Effects of Acetaminophen Exposure on Outcomes of Patients Receiving Immune Checkpoint Inhibitors for Advanced Non-Small-Cell Lung Cancer: A Propensity Score-Matched Analysis

2023 · Fabrizio Nelli, Antonella Virtuoso, et al. · Current Oncology · 10

Dynamic changes in peripheral lymphocytes and antibody response following a third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients

2022 · Enzo Maria Ruggeri, Fabrizio Nelli, et al. · Scientific Reports · 10

Six month immunogenicity of COVID-19 mRNA-BNT162b2 vaccine in actively treated cancer patients: updated results of the Vax-On study

2021 · F. Nelli, A. Fabbri, et al. · Annals of Oncology · 9

Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study

2021 · E.M. Ruggeri, F. Nelli, et al. · ESMO Open · 9

Peripheral lymphocyte subset counts predict antibody response after SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients: Results from the Vax-On-Profile study

2022 · Fabrizio Nelli, Agnese Fabbri, et al. · International Immunopharmacology · 8

Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study

2022 · F. Nelli, D. Giannarelli, et al. · Annals of Oncology · 8

Changes in Peripheral Immune Cells after the Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine and Disease Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Prospective Analysis of the Vax-on-Third-Profile Study

2023 · Fabrizio Nelli, Carlo Signorelli, et al. · Cancers · 7

Impact of previous corticosteroid exposure on outcomes of patients receiving immune checkpoint inhibitors for advanced non-small cell lung cancer: a retrospective observational study

2022 · F. Nelli, A. Virtuoso, et al. · Cancer Chemotherapy and Pharmacology · 7

Immune-related Thyroid Dysfunction (irTD) in Non-small Cell Lung Cancer (NSCLC) Correlates With Response and Survival

2022 · MARIO GIOVANNI CHILELLI, CARLO SIGNORELLI, et al. · Cancer Diagnosis & Prognosis · 7

Multimodal treatment for local recurrent malignant gliomas: Resurgery and/or reirradiation followed by chemotherapy

2018 · Arsela Prelaj, Sara Rebuzzi, et al. · Molecular and Clinical Oncology · 7

Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors

2023 · Fabrizio Nelli, Diana Giannarelli, et al. · Cancer Immunology Immunotherapy · 6

An Italian multicenter retrospective real-life analysis of patients with brain metastases from renal cell carcinoma: the BMRCC study

2023 · V. Internò, F. Massari, et al. · ESMO Open · 5

Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study

2023 · Fabrizio Nelli, Agnese Fabbri, et al. · Current Oncology · 5

Herpes zoster after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: a prospective study

2024 · Fabrizio Nelli, Agnese Fabbri, et al. · Clinical and Experimental Medicine · 4

Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: a prospective study

2023 · Fabrizio Nelli, Agnese Fabbri, et al. · Frontiers in Oncology · 3

Dynamic Changes of Peripheral NK Cells Predict Outcome in Patients with PD-L1 Positive Non-small-cell Lung Cancer Undergoing Immune Checkpoint Inhibitors as Second-line Therapy

2022 · Fabrizio Nelli, Valentina Panichi, et al. · Cancer Investigation · 3

Long-Term Complete Response and Survival in Metastatic Extramammary Paget’s Disease Treated With Trastuzumab Plus Paclitaxel: A Case Report

2024 · Mario Giovanni Chilelli, Carlo Signorelli, et al. · Cureus · 2

94P: First-line treatment with cisplatin plus etoposide for small cell lung cancer and large cell neuroendocrine carcinoma: Our center experience

2016 · G. Del Bene, A. Prelaj, et al. · Journal of Thoracic Oncology · 2

Works count: 32

Citation count: 351

H-index: 9

I10-index: 9